Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPULSE trial of empagliflozin in stabilized patients hospitalized for acute heart failure
2019-002946-19Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Acute Heart Failure (AHF) and heart failure (HF) comparing Empagliflozin with Placebo (2 arms). Primary endpoint: Clinical benefit. Started Dec 2019; status: completed.
02
Drugs
empagliflozin
03
Conditions
Acute Heart Failure (AHF)heart failure (HF)
Beyond the preview
Go deeper on 2019-002946-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002946-19.